Nevro

Quote




























































NEVRO will lose a lot of talented reps due to Rami's HITLER-ESQUE style combined with quotas that change from quarter to quarter. Plus, significant explants coupled with BURST taking share is unnerving to most of these reps that had a good, uncontested run.
 






in 2018, Nevro will become the market leader the US as they already have in Australia and Europe for the rechargeable segment.

SJM leads the world in explants due to hawking primary cell batteries to almost all their patients. Burst has a higher explant rate and can't come close to the pain relief provided by HF10. 3-4 primary cell batteries will be burned through in the life of one Nevro implant. The payers are taking notice, and hopefully this unethical business model of SJM will end for the sake of the patient.
 






anonymous said:
in 2018, Nevro will become the market leader the US as they already have in Australia and Europe for the rechargeable segment.

SJM leads the world in explants due to hawking primary cell batteries to almost all their patients. Burst has a higher explant rate and can't come close to the pain relief provided by HF10. 3-4 primary cell batteries will be burned through in the life of one Nevro implant. The payers are taking notice, and hopefully this unethical business model of SJM will end for the sake of the patient.
Click to expand...

no argument with any of that...
 






anonymous said:
in 2018, Nevro will become the market leader the US as they already have in Australia and Europe for the rechargeable segment.

SJM leads the world in explants due to hawking primary cell batteries to almost all their patients. Burst has a higher explant rate and can't come close to the pain relief provided by HF10. 3-4 primary cell batteries will be burned through in the life of one Nevro implant. The payers are taking notice, and hopefully this unethical business model of SJM will end for the sake of the patient.
Click to expand...

Agreed. US market leadership is the goal, and Nevro will get there.

What will field sales turnover rate be by 2018? How many of the talented, passionate people who launched the therapy and "took the arrows" will still be around? Will talented people still come over, just to work for the market leader?
 


















anonymous said:
1. Stim Wave
2. Nuvectra
3. Nevro
4. Medtronic
5. Boston Scientific
6. St. Jude/Abbot
Click to expand...

StJ, Mdt and Boston, all losing mrkt share big, to Nevro. Look at trend because the dominoes are falling. By 2018-19, Nevro will sit atop the Leader Board which is remarkable considering they are just two years in from US mrkt launch.
 
























Top Bottom
Back
Quote